Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Webinar: Aligning Biosimilar Access Policy With Global Health Priorities

November 14th 2025

By Skylar Jeremias

Video

FDA Quietly Approves Denosumab Biosimilars, Issues Interchangeability for Others

November 13th 2025

By Skylar Jeremias

Article

FDA approves multiple denosumab biosimilars, enhancing market access and introducing interchangeability, boosting competition in bone health therapies.

Global Data Show Variety in Adalimumab Biosimilar Design, Patient Support Systems

November 7th 2025

By Skylar Jeremias

Article

New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences.

Biosimilar Monthly Roundup: October 2025

November 6th 2025

By Skylar Jeremias

Article

October 2025 marks a transformative period for biosimilars, with new FDA guidelines accelerating approvals and promising significant cost savings for health care.

Data Confirm Biosimilar Bmab 1200 Performance in Psoriasis Through 1 Year

November 6th 2025

By Skylar Jeremias

Article

New clinical data confirms Bmab 1200, a biosimilar to ustekinumab, offers equivalent efficacy and safety for treating moderate to severe plaque psoriasis.

UK Experts Publish Guidance on JC Virus Testing for Natalizumab Biosimilar Tyruko

November 5th 2025

By Skylar Jeremias

Article

UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing safety and monitoring challenges.

Global Regulatory Gridlock Hinders Biosimilar Savings, Expert Panel Warns

November 4th 2025

By Skylar Jeremias

Article

A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.

A Closer Look at New FDA Guidance Removing Barriers to Biosimilar Development

October 30th 2025

By Skylar Jeremias

Article

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability.

BioRationality: The FDA Sets Sights on Removing Clinical Efficacy Studies for Biosimilars

October 29th 2025

By Sarfaraz K. Niazi, PhD

Article

Biosimilars Improve Health System Resilience in Latin American, Caribbean Nations

October 28th 2025

By Skylar Jeremias

Article

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for chronic conditions and oncology.